LAM Treatment Alliance Fast Tracking Treatment Research

State of the Science

Discovering new treatments for LAM requires a multidisciplinary approach, bringing together laboratory and clinical researchers from diverse areas of expertise--for example, those interested in cell signaling, estrogen biology, pulmonary pathophysiology, vascular biology, and cancer, among other disciplines. It is an approach that is in line with the multidisciplinary perspective outlined by the U.S. National Institutes of Health (NIH) Roadmap for Medical Research, and is as a guiding principal for research funding and support.

To foster interdisciplinary collaboration to find a LAM treatment or cure, the LTA actively recruits the best and the brightest researchers in the world to work on LAM, sponsors seminars focused on finding an effective LAM treatment or cure, and convenes regular high-powered brainstorming and problem-solving meetings and summits for the scientific, medical, and even patient communities.

Moreover, LTA matches the highest-priority research projects with the researchers, labs and institutions best equipped to execute them. We recruit scientists, facilitate research collaborations and accept and review research proposals on a rolling basis. We facilitate the highest quality and highest impact LAM research by funding scientific awards, supporting increased dialogue and collaboration among LAM researchers and leaders in relevant fields across disciplines and institutions.

Sponsoring, recruiting, convening and promoting LAM research, we bring together the best and the brightest minds from diverse areas of expertise to focus on finding a treatment for LAM in the fastest time possible. We aggressively fund high-impact collaborative research initiatives, such as:

  • Over 85 ad hoc or "as needed" meetings each year;
  • Monthly seminars at Harvard Medical School accessible to researchers and clinicians globally;
  • International state-of-the-science Summits held on an as-needed basis throughout the year;
  • Fostering and funding travel grants to over 75 researchers per year to attend face-to-face problem solving meetings and to get the training they need in specialized laboratories throughout the world;
  • Connecting Patients and Researchers. Clinical care that stays on the cutting edge of research developments;
  • Facilitating Patient-Researcher contact earlier in the research process than is traditionally the case;
  • Innovating to ensure that information that patients choose to share about their experience of their disease accessible in appropriate ways and used efficiently and effectively by the research and clinical communities;
  • Supporting patient access to expert informed specialist care for effective disease management at top-level institutions throughout the world from pulmonology to reproductive endocrinology and interventional radiology;
  • Eliminating Barriers. Prioritizing work to overcome key barriers to accelerating treatment research;
  • Ensuring fast and effective tissue procurement, banking, distribution;
  • Supporting patient efforts to become tissue donors; Supporting researcher interest in efficient access to LAM tissue;
  • Strategic focus of resources to overcome cell isolation/ cell culturing/ cell line growth challenges and barriers to effective disease models;
  • Working to ensure that resources spent on LAM at all stages and in all areas of research and infrastructure development for the community are coordinated to ensure maximum impact from any investment;
  • Fast-Tracking Core Research, such as leveraging leading-edge expertise and cutting-edge technologies to advance LAM research in Radiographic and other forms of Biomarker identification to enable detection of response to therapy in advance of conventional measures, the identification of additional genes implicated in LAM, genotyping / expression analyses, and high-throughput combination drug screening using libraries of already approved drugs.